|Articles|October 26, 2010
Mid*Lands IRB, LLC-First Independent IRB in Kansas Awarded Accreditation for Protecting Research Participants
Advertisement
Mid*Lands IRB
, LLC is pleased to announce that it has been awarded accreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP) at the September meeting of its Council on Accreditation.
Located in the Kansas City metro area, Mid*Lands is an independent review board (IRB) that protects the rights and welfare of research study participants. Mid*Lands IRB specializes in providing customized, personalized, and responsive services for its client partners. Mid*Lands provides IRB review for clients nationwide for all phases of research in all therapeutic areas. Mid*Lands has extensive experience in multi-site trials, with two Boards that meet weekly.
AAHRPP promotes high-quality research through an accreditation process that helps organizations worldwide strengthen their human research protection programs (HRPPs).
An independent, non-profit accrediting body, AAHRPP uses a voluntary, peer-driven, educational model to ensure that HRPPs meet rigorous standards for quality and protection. To earn accreditation, organizations must provide tangible evidence through policies, procedures, and practices of their commitment to scientifically and ethically sound research and continuous improvement.
As the "gold seal," AAHRPP accreditation offers assurances to research participants, researchers, sponsors, government regulators, and the general public that an HRPP is focused first and foremost on excellence.
"After a tremendous amount of work by both our staff and our IRB Members, Mid*Lands has achieved full accreditation," according to Cathy Owen, CIM, CIP, CCRP, President and CEO of Mid*lands. "The rigorous and comprehensive accreditation mandated by AAHRPP provides Mid*Lands with the ability to achieve even higher levels of protection for human research participants," Ms. Owen said.
Located in the Kansas City metro area, Mid*Lands is an independent review board (IRB) that protects the rights and welfare of research study participants. Mid*Lands IRB specializes in providing customized, personalized, and responsive services for its client partners. Mid*Lands provides IRB review for clients nationwide for all phases of research in all therapeutic areas. Mid*Lands has extensive experience in multi-site trials, with two Boards that meet weekly.
AAHRPP promotes high-quality research through an accreditation process that helps organizations worldwide strengthen their human research protection programs (HRPPs).
An independent, non-profit accrediting body, AAHRPP uses a voluntary, peer-driven, educational model to ensure that HRPPs meet rigorous standards for quality and protection. To earn accreditation, organizations must provide tangible evidence through policies, procedures, and practices of their commitment to scientifically and ethically sound research and continuous improvement.
As the "gold seal," AAHRPP accreditation offers assurances to research participants, researchers, sponsors, government regulators, and the general public that an HRPP is focused first and foremost on excellence.
"After a tremendous amount of work by both our staff and our IRB Members, Mid*Lands has achieved full accreditation," according to Cathy Owen, CIM, CIP, CCRP, President and CEO of Mid*lands. "The rigorous and comprehensive accreditation mandated by AAHRPP provides Mid*Lands with the ability to achieve even higher levels of protection for human research participants," Ms. Owen said.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement